OTC Healthcare in Tunisia
Euromonitor International's OTC Healthcare in Tunisia market report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.
Get immediate access to strategic market analysis when you buy reports online
Tables: 14 | Publication date: Jan 2007
Why buy this report
- Get insight into trends in market performance
- Pinpoint growth sectors and identify factors driving change
- Identify market and brand leaders and understand the competitive environment
Product coverage
Adult mouthcare; Allergy care; Analgesics; Calming and sleeping products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; Digestive remedies; Ear care; Emergency contraception; Eye care; Medicated skin care; NRT Smoking cessation aids; OTC obesity; OTC statins; Vitamins and dietary supplements; Wound treatments
Executive summary
Controlled growth in unit prices supports sales growth
The Tunisian government continues to exercise strict controls on OTC healthcare. Sales and advertising are restricted to chemists/pharmacies and imports, distribution and pricing are controlled by government bodies. High fees for doctors’ consultations support high levels of self-medication, which the government is attempting to reduce through education campaigns and this raft of restrictions. Unit price increases in 2005 underpinned good growth in overall OTC healthcare, although both price increases and sales growth declined in comparison to that seen in 2004.
Calming and sleeping products and ear care benefit from consumer education
At the start of the review period, many consumers purchased antihistamines as a remedy for mild sleeplessness, while antibiotics were often used for ear infections. Government education campaigns targeting consumers and chemists/pharmacies encouraged the use of specific calming and sleeping products and ear care instead. This resulted in good growth for these product areas, although this was further exaggerated by a low base.
Multinationals facing the increasing strength of domestic players
Multinationals continued to dominate sales of OTC healthcare in 2005, with Bristol-Myers Squibb UPSA Tunisie being the leading player. However, domestic players benefited from legislation introduced at the start of 2005 prohibiting the import of OTC healthcare where equivalent domestic products are available. This mainly reduced the range of imported generics available in Tunisia but also supported good growth in share for domestic players, particularly state-owned SIPHAT.
Distribution likely to remain limited in forecast period
The distribution of OTC healthcare was limited to chemists/pharmacies during the review period and is expected to remain restricted in this manner during the forecast period. Furthermore, chemists/pharmacies are themselves prohibited from forming chains or from utilising price promotions or promotional leaflets. Consequently, retailer activity has little impact on sales of OTC healthcare, with growth mainly shaped by the government.
Steady growth in forecast period
Most areas of OTC healthcare are expected to see even constant value growth during the forecast period, with growth largely stemming from the government’s unit price increases. Some niche products, such as calming and sleeping products, will benefit from continued education campaigns. Other products will benefit from advertising on satellite television, such as analgesics. Generally, however, OTC healthcare will be characterised by even growth and the increasing strength of domestic players during the forecast period.
Table of contents
OTC HEALTHCARE IN TUNISIA : MARKET INSIGHT
1. EXECUTIVE SUMMARY
2. OPERATING ENVIRONMENT
2.1 OTC Registration and Classification
2.2 Vitamins & Dietary Supplements Registration and Classification
2.3 Advertising
2.4 Packaging and Labelling
2.5 Distribution
2.6 De-listing or De-reimbursement
2.7 Traditional Remedies
2.8 Homeopathy
2.9 Generics
2.10 Consumer Expenditure on Health Goods and Medical Services
Table 1 Consumer Expenditure on Health Goods and Medical Services 2000-2005
2.11 Life Expectancy
Table 2 Life Expectancy at Birth 2000-2005
3. OTC HEALTHCARE SALES
3.1 Market Performance
Table 3 Retail Sales of OTC Healthcare by Sector: Value 2000-2005
Table 4 Retail Sales of OTC Healthcare by Sector: % Value Growth 2000-2005
3.2 Switches
3.3 Competitive Environment
Table 5 OTC Healthcare Company Shares by Retail Value 2001-2005
Table 6 OTC Healthcare Brand Shares by Retail Value 2002-2005
3.4 Leading Company Profile: Societe des Industries Pharmaceutiques de Tunisie
Summary 1 Societe des Industries Pharmaceutiques de Tunisie: Operational Indicators 2005
3.5 Leading Company Profile: Laboratoires Opalia Tunisie
Summary 2 Laboratoires Opalia Tunisie: Operational Indicators 2005
Summary 3 Laboratoires Opalia Tunisie: Production Statistics 2005
3.6 New Product Developments
Summary 4 OTC Healthcare: New Product Launches 2004-2005
3.7 Retail Distribution
Table 7 Retail Sales of OTC Healthcare by Distribution Format: % Analysis 2000/2005
Table 8 Retail Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2005
3.8 Retailer Activity and Private Label Trends
3.9 Forecast Market Performance
Table 9 Forecast Retail Sales of OTC Healthcare by Sector: Value 2005-2010
Table 10 Forecast Retail Sales of OTC Healthcare by Sector: % Value Growth 2005-2010
4. DEFINITIONS